BioCardia (BCDA) Non-Current Assets (2010 - 2026)
BioCardia's (BCDA) quarterly Non-Current Assets came in at $457000.0 in Q2 2026, down 48.65% year-over-year from $890000.0 in Q2 2025, and down 20.1% quarter-over-quarter from $572000.0 in Q1 2026.
Analysis
BioCardia (BCDA) Non-Current Assets (2010 - 2026) Analysis & Trends
BioCardia (BCDA) has reported Non-Current Assets for 13 consecutive years, with $457000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 48.65% year-over-year to $457000.0 in Q2 2026; TTM through Jun 2026 was $2.5 million, a 40.59% decrease from a year earlier, with the FY2025 full-year figure at $681000.0, down 38.2% from the prior year.
- Non-Current Assets was $457000.0 for Q2 2026 at BioCardia, down from $572000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $2.2 million in Q1 2022 and troughed at $457000.0 in Q2 2026.
- A 5-year average of $1.4 million and a median of $1.4 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 525.0% in 2022 and plunged 48.65% in 2026, its largest moves.
- Over 5 years, Non-Current Assets stood at $1.9 million in 2022, then slipped by 20.89% to $1.5 million in 2023, then dropped by 27.79% to $1.1 million in 2024, then plunged by 38.2% to $681000.0 in 2025, then tumbled by 32.89% to $457000.0 in 2026.
- The last three Non-Current Assets figures came in at $457000.0 (Q2 2026), $572000.0 (Q1 2026), and $681000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 441.00 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | 279.00 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 451.27 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 523.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 150.83 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 207.76 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 35.91 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 964.69 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 238.14 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | 457,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 457,000.00 |
| Mar 31, 2026 | 572,000.00 |
| Dec 31, 2025 | 681,000.00 |
| Sep 30, 2025 | 783,000.00 |
| Jun 30, 2025 | 890,000.00 |
| Mar 31, 2025 | 993,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 1.74 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 2.03 Mn |
| Jun 30, 2022 | 2.11 Mn |
| Mar 31, 2022 | 2.18 Mn |
| Dec 31, 2021 | 2.24 Mn |
| Sep 30, 2021 | 324,000.00 |